Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 9/2018

01-09-2018 | Pictorial essay

The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges

Authors: Esma A. Akin, Elsa Stephen Kuhl, Robert K. Zeman

Published in: Abdominal Radiology | Issue 9/2018

Login to get access

Abstract

All women, during their lifetime, are at risk of developing some form of gynecologic malignancy. The role of FDG-PET/CT has become more established in the management of gynecologic malignancies in the last decade. In this article, we will review the role of FDG-PET/CT in endometrial, cervical, ovarian, and vaginal cancer, by highlighting its strengths and limitations. While the role in initial or pre-operative staging for FDG-PET/CT is controversial, it allows noninvasive detection of equivocal or distant metastases, may alter stage and prognosis, and can guide or help eliminate unnecessary interventions that may not be beneficial. FDG-PET/CT is a useful adjunct to traditional staging with MR and CT.
Literature
1.
2.
3.
Plaxton N, Polsani A, Halkar R, Godette K, Barron B (2012) FDG PET/CT utility in gynecologic malignancies: a comprehensive interactive review of anatomy, pathways of metastatic spread and scan findings. J Nucl Med 53:1067
4.
Nogami Y, Iida M, Banno K, et al. (2014) Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects. Anticancer Res 34:585–592PubMed
5.
6.
Sharma P, Kumar R, Singh H, et al. (2012) Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37:649–655CrossRefPubMed
7.
Lioupis M, Syrmos N (2016) Nuclear Medicine and its promising applications in gynecological cancers. Hell J Nucl Med 19:63PubMed
8.
Micco M, Sala E, Lakhman Y, Hricak H, Vargas HA (2014) Role of imaging in the pretreatment evaluation of common gynecological cancers. Womens Health (Lond) 10:299–321CrossRef
9.
NCCN Practice Guidelines Narrative Summary of Indications for FDG PET and PET/ CT. 2/14/2016 ed2016.
10.
Prat J (2015) Oncology FCoG. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26:87–89CrossRefPubMedPubMedCentral
11.
Kitajima K, Murakami K, Kaji Y, Sugimura K (2010) Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol 195:737–743CrossRefPubMed
12.
Park JY, Kim EN, Kim DY, et al. (2008) Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 108:486–492CrossRefPubMed
13.
Picchio M, Mangili G, Samanes Gajate AM, et al. (2010) High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging. Nucl Med Commun 31:506–512PubMed
14.
Kang SY, Cheon GJ, Lee M, et al. (2017) Prediction of recurrence by preoperative intratumoral FDG uptake heterogeneity in endometrioid endometrial cancer. Transl Oncol 10:178–183CrossRefPubMedPubMedCentral
15.
Benedetti Panici P, Basile S, Maneschi F, et al. (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRefPubMed
16.
Freeman SJ, Aly AM, Kataoka MY, et al. (2012) The revised FIGO staging system for uterine malignancies: implications for MR imaging. Radiographics 32:1805–1827CrossRefPubMed
17.
Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K (2009) Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol 19:1529–1536CrossRefPubMed
18.
Nakahara T, Fujii H, Ide M, et al. (2001) F-18 FDG uptake in endometrial cancer. Clin Nucl Med 26:82–83CrossRefPubMed
19.
Chander S, Meltzer CC, McCook BM (2002) Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med 27:22–24CrossRefPubMed
20.
Lerman H, Metser U, Grisaru D, et al. (2004) Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 45:266–271PubMed
21.
Peltomaki P, Butzow R (2011) Pathogenesis of endometriosis and its relationship to gynecological cancers. Epigenomics 3:689–690CrossRefPubMed
22.
Saga T, Higashi T, Ishimori T, et al. (2003) Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 17:197–203CrossRefPubMed
23.
Survival rates for Ovarian Cancer by Stage. 2016.
24.
Tjalma WA, Carp L, De Beeck BO (2004) False-positive positron emission tomographic scan and computed tomography for recurrent vaginal cancer: pitfalls of modern imaging techniques. Gynecol Oncol 92:726–728CrossRefPubMed
25.
Fenchel S, Grab D, Nuessle K, et al. (2002) Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 223:780–788CrossRefPubMed
26.
Castellucci P, Perrone AM, Picchio M, et al. (2007) Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 28:589–595CrossRefPubMed
27.
Grab D, Flock F, Stohr I, et al. (2000) Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 77:454–459CrossRefPubMed
28.
Yoshida Y, Kurokawa T, Kawahara K, et al. (2004) Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 182:227–233CrossRefPubMed
29.
Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER (2005) FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97:183–191CrossRefPubMed
30.
Woodward PJ, Hosseinzadeh K, Saenger JS (2004) From the archives of the AFIP. Radiographics 24:225–246CrossRefPubMed
31.
Keidar Z, Amit A, Lowenstein L, Israel O (2015) The role of FDG-PET/CT in predicting secondary optimal debuling in patients with recurrent ovarian cancer. J Nucl Med 56:1346
32.
Miller DS, Spirtos NM, Ballon SC, et al. (1992) Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 69:502–510CrossRefPubMed
33.
Kubik-Huch RA, Dorffler W, von Schulthess GK, et al. (2000) Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 10:761–767CrossRefPubMed
34.
Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50:64S–73SCrossRefPubMed
35.
Avril N, Sassen S, Schmalfeldt B, et al. (2005) Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23:7445–7453CrossRefPubMed
36.
Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW (2001) Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 82:17–21CrossRefPubMed
37.
Markowitz LE, Unger ER, Saraiya M (2009) Primary and secondary prevention of cervical cancer–opportunities and challenges. J Natl Cancer Inst 101:439–440CrossRefPubMed
38.
Togashi K, Morikawa K, Kataoka ML, Konishi J (1998) Cervical cancer. J Magn Reson Imaging 8:391–397CrossRefPubMed
39.
Dehdashti F, Siegel BA (2010) Gynecological tumors. In: Delbeke D, Israel O (eds) Hybrid PET/CT and SPECT/CT imaging: a teaching file. New York: Springer, pp 383–408CrossRef
40.
Pandit-Taskar N (2005) Oncologic imaging in gynecologic malignancies. J Nucl Med 46:1842–1850PubMed
41.
Grigsby PW, Siegel BA, Dehdashti F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19:3745–3749CrossRefPubMed
42.
Kidd EA, Siegel BA, Dehdashti F, et al. (2010) Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 28:2108–2113CrossRefPubMed
43.
Lukka H, Hirte H, Fyles A, et al. (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer–a meta-analysis. Clin Oncol (R Coll Radiol) 14:203–212CrossRef
44.
45.
Bodurka-Bevers D, Morris M, Eifel PJ, et al. (2000) Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78:187–193CrossRefPubMed
46.
Jacobs AJ, Faris C, Perez CA, et al. (1986) Short-term persistence of carcinoma of the uterine cervix after radiation. An indicator of long-term prognosis. Cancer 57:944–950CrossRefPubMed
47.
Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298:2289–2295CrossRefPubMed
48.
Lamoreaux WT, Grigsby PW, Dehdashti F, et al. (2005) FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 62:733–737CrossRefPubMed
49.
Koh WJ, Greer BE, Abu-Rustum NR, et al. (2017) Vulvar cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:92–120CrossRef
50.
Cohn DE, Dehdashti F, Gibb RK, et al. (2002) Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 85:179–184CrossRefPubMed
51.
Vaginal Cancer Treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD)2002.
52.
Robertson NL, Hricak H, Sonoda Y, et al. (2016) The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. Gynecol Oncol 140:420–424CrossRefPubMedPubMedCentral
Metadata
Title
The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges
Authors
Esma A. Akin
Elsa Stephen Kuhl
Robert K. Zeman
Publication date
01-09-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 9/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1441-8

Other articles of this Issue 9/2018

Abdominal Radiology 9/2018 Go to the issue

OriginalPaper

Measuring liver T2* and cardiac T2* in a single acquisition

OriginalPaper

Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla

OriginalPaper

ADC similarity predicts microvascular invasion of bifocal hepatocellular carcinoma

OriginalPaper

Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement

Pictorial essay

Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients

OriginalPaper

Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits